A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
Recruiting
Phase 1
Interventional Study
Hepatic Insufficiency
Liver Diseases
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 16 (estimated)
- Sponsor
- Incyte Corporation · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with moderate or severe hepatic impairment.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Ability to comprehend and willingness to sign a written ICF for the study.
* Aged 18 to 80 years, inclusive, at the time of signing the ICF.
* Moderate or severe hepatic impairment based on CP score.
* Medical findings consistent with the degree of hepatic dysfunction, determi…
Contacts